![Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors | Nature Communications Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-19540-z/MediaObjects/41467_2020_19540_Fig1_HTML.png)
Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors | Nature Communications
![Frontiers | Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? Frontiers | Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?](https://www.frontiersin.org/files/Articles/427647/fimmu-09-03107-HTML/image_m/fimmu-09-03107-g001.jpg)
Frontiers | Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
![Cancer Treatment May Inhibit Immune Response to COVID-19 Vaccination - Infectious Disease Special Edition Cancer Treatment May Inhibit Immune Response to COVID-19 Vaccination - Infectious Disease Special Edition](https://www.idse.net/aimages/2022/COVIDmRNA_thumb.jpg)
Cancer Treatment May Inhibit Immune Response to COVID-19 Vaccination - Infectious Disease Special Edition
![Cancer Patients on Chemotherapy Likely Not Fully Protected by COVID-19 Vaccine | University of Arizona News Cancer Patients on Chemotherapy Likely Not Fully Protected by COVID-19 Vaccine | University of Arizona News](https://cdn.uanews.arizona.edu/s3fs-public/vaccine-header-image.jpg)
Cancer Patients on Chemotherapy Likely Not Fully Protected by COVID-19 Vaccine | University of Arizona News
![Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet](https://www.thelancet.com/cms/attachment/0d3d5972-77c1-4161-bbf6-a21c4ab51b4a/gr1.gif)
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet
![Vaccines | Free Full-Text | The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy Vaccines | Free Full-Text | The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy](https://www.mdpi.com/vaccines/vaccines-04-00043/article_deploy/html/images/vaccines-04-00043-g001.png)
Vaccines | Free Full-Text | The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy
![Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms: Molecular Therapy Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms: Molecular Therapy](https://www.cell.com/cms/attachment/b020619a-c165-4051-a825-cdb6a00ec5fc/gr1.jpg)
Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms: Molecular Therapy
![COVID-19 vaccines for patients with cancer: benefits likely outweigh risks | Journal of Hematology & Oncology | Full Text COVID-19 vaccines for patients with cancer: benefits likely outweigh risks | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01046-w/MediaObjects/13045_2021_1046_Fig1_HTML.png)
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks | Journal of Hematology & Oncology | Full Text
![An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression | Science Advances An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression | Science Advances](https://www.science.org/cms/10.1126/sciadv.abj4796/asset/f275c8b8-b1de-4cbf-acd1-2d86f476697c/assets/images/large/sciadv.abj4796-f1.jpg)
An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression | Science Advances
![Humoral and cellular response to primary and booster COVID-19 vaccination in immunosuppressed patients Humoral and cellular response to primary and booster COVID-19 vaccination in immunosuppressed patients](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_701152_16418231406198667.jpg)
Humoral and cellular response to primary and booster COVID-19 vaccination in immunosuppressed patients
![Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors | Nature Reviews Clinical Oncology Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-020-0413-z/MediaObjects/41571_2020_413_Fig1_HTML.png)